Merck Sharp & Dohme 8-K Merck Reports Second-Quarter 2008 Financial Results

Exhibit 99.2

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

SECOND QUARTER

2008

EQUITY INCOME FROM AFFILIATES (millions of dollars)

	2Q `08		2Q `07		YTD 2008		YTD 2007
MERCK / SCHERING-PLOUGH	$	365.2	$	465.1	$	758.0	$	812.2
ASTRAZENECA LP		61.4		215.1		192.5		427.1
Other(1)		96.4		78.9		224.6		172.4
TOTAL	$	523.0	$	759.1	$	1,175.1	$	1,411.7

⁽¹⁾ Primarily reflects results for Merial Limited, Sanofi Pasteur-MSD and Johnson & JohnsonºMerck Consumer Pharmaceuticals.

JOINT VENTURE SALES DETAIL (millions of dollars)

All sales reported here are end-market JV sales, presented on a “NET” basis.

Merial	2Q `08		2Q `07		YTD 2008		YTD 2007
FRONTLINE, other fipronil	$	306.1	$	296.8	$	647.7	$	624.4
BIOLOGICALS		208.5		157.5		382.9		310.8
IVOMEC, HEARTGARD, other avermectins		140.3		116.5		286.4		253.9
Other Animal Health		77.2		65.9		148.7		125.3
TOTAL MERIAL SALES	$	732.1	$	636.7	$	1,465.7	$	1,314.4
Sanofi Pasteur-MSD	2Q `08		2Q `07		YTD 2008		YTD 2007
GARDASIL	$	234.2	$	77.8	$	474.0	$	108.0
VIRAL VACCINES		29.1		24.2		51.8		44.3
HEPATITIS VACCINES		19.4		19.2		37.4		35.9
Other Vaccines		147.3		143.6		278.2		271.4
TOTAL SANOFI PASTEUR-MSD SALES	$	430.0	$	264.8	$	841.4	$	459.6
Merck / Schering-Plough Collaboration	2Q `08		2Q `07		YTD 2008		YTD 2007
VYTORIN	$	592.1	$	686.4	$	1,243.3	$	1,310.2
ZETIA		560.4		577.5		1,142.1		1,121.5
TOTAL MERCK / SCHERING-PLOUGH SALES	$	1,152.5	$	1,263.9	$	2,385.4	$	2,431.7

OTHER (INCOME) EXPENSE, NET (millions of dollars)

	2Q `08			2Q `07			YTD 2008			YTD 2007
INTEREST INCOME	$	(143.4	)	$	(172.3	)	$	(313.0	)	$	(354.0	)
INTEREST EXPENSE		50.6			103.3			123.2			205.7
EXCHANGE LOSSES (GAINS)		8.7			(12.0	)		21.3			(31.6	)
MINORITY INTERESTS		30.9			30.8			62.8			61.4
Other, net(1)		(28.7	)		(33.8	)		(2,153.5	)		(221.7	)
TOTAL	$	(81.9	)	$	(84.0	)	$	(2,259.2	)	$	(340.2	)

⁽¹⁾ Other, net for the first six months of 2008 primarily reflects a gain of $2.2 billion related to a distribution from AstraZeneca LP.

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

SECOND QUARTER

2008

NET PRODUCT SALES DETAIL (millions of dollars)

	2Q `08 vs. 2Q `07
	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
PRODUCT
COZAAR / HYZAAR	11	%	941	5	%	315	15	%	626
FOSAMAX	-48	%	411	-76	%	123	3	%	288
SINGULAIR	-1	%	1,082	-8	%	710	15	%	372
Vaccines:
GARDASIL	-9	%	326	-11	%	255	-1	%	71
ROTATEQ	49	%	178	46	%	166	*		12
ZOSTAVAX	41	%	66	41	%	66	N/A		—
OTHER VIRAL VACCINES(1)	-7	%	318	-11	%	291	61	%	27
HEPATITIS VACCINES	-52	%	38	-58	%	29	-21	%	9
OTHER VACCINES	-28	%	69	-52	%	33	34	%	37
Other Reported Products:
ARCOXIA	17	%	104	N/A		—	17	%	104
CANCIDAS	20	%	161	-25	%	26	36	%	135
COSOPT / TRUSOPT	13	%	217	3	%	87	22	%	130
CRIXIVAN / STOCRIN	5	%	79	-39	%	3	8	%	76
EMEND	39	%	65	27	%	41	63	%	25
INVANZ	53	%	71	30	%	34	82	%	37
ISENTRESS	*		77	*		45	*		32
JANUVIA	*		334	91	%	262	*		72
JANUMET	*		72	*		67	*		5
MAXALT	20	%	130	18	%	86	23	%	45
PRIMAXIN	8	%	201	-19	%	41	19	%	160
PROPECIA	10	%	108	-3	%	38	18	%	70
PROSCAR	-24	%	86	-83	%	3	-11	%	83
TIMOPTIC / TIMOPTIC XE	4	%	32	-16	%	2	5	%	30
VASOTEC / VASERETIC	-27	%	94	N/A		—	-27	%	94
ZOCOR	-1	%	177	*		19	-10	%	157
ZOLINZA	—		3	-7	%	3	N/A		—

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	2Q '08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	6,052	-1	%	-4	-1	5
U.S. ($ MM)		3,341	-10	%	-10	—	N/A
Foreign ($ MM)		2,711	12	%	5	-4	12

MERCK & CO., INC.

OTHER FINANCIAL DISCLOSURES

JUNE YEAR-TO-DATE

2008

NET PRODUCT SALES DETAIL (millions of dollars)

	JUNE YTD '08 vs. JUNE YTD '07
PRODUCT	TOTAL % CHG		TOTAL $	U.S. % CHG		U.S. $	Foreign % CHG		Foreign $
COZAAR / HYZAAR	9	%	1,788	1	%	614	13	%	1,174
FOSAMAX	-42	%	881	-67	%	326	3	%	555
SINGULAIR	4	%	2,185	-4	%	1,424	24	%	761
Vaccines:
GARDASIL	-1	%	716	-8	%	548	34	%	168
ROTATEQ	80	%	368	76	%	345	*		22
ZOSTAVAX	56	%	140	56	%	140	N/A		—
OTHER VIRAL VACCINES(1)	-8	%	543	-11	%	493	42	%	51
HEPATITIS VACCINES	-53	%	72	-58	%	53	-21	%	18
OTHER VACCINES	-24	%	142	-54	%	62	49	%	80
Other Reported Products:
ARCOXIA	17	%	197	N/A		—	17	%	197
CANCIDAS	15	%	310	-23	%	56	30	%	254
COSOPT / TRUSOPT	11	%	419	—		168	19	%	251
CRIXIVAN / STOCRIN	-2	%	154	-38	%	7	1	%	147
EMEND	32	%	125	19	%	81	64	%	44
INVANZ	43	%	126	27	%	62	63	%	64
ISENTRESS	*		124	*		75	*		49
JANUVIA	*		606	*		490	*		116
JANUMET	*		131	*		122	*		9
MAXALT	16	%	252	14	%	164	20	%	87
PRIMAXIN	6	%	404	-17	%	92	15	%	312
PROPECIA	10	%	213	-1	%	75	17	%	138
PROSCAR	-28	%	171	-86	%	6	-14	%	165
TIMOPTIC / TIMOPTIC XE	2	%	61	-15	%	3	4	%	57
VASOTEC / VASERETIC	-24	%	189	N/A		—	-24	%	189
ZOCOR	-18	%	356	-34	%	48	-15	%	308
ZOLINZA	32	%	7	23	%	6	*		1

* 100% or over

N/A - Not Applicable

⁽¹⁾ - Includes ProQuad, M-M-R II and Varivax.

TOTAL SALES: VOLUME, PRICE, EXCHANGE

	JUN YTD '08		% CHG		VOL	PX	FX
TOTAL PHARMACEUTICAL SALES	$	11,874	—	%	-3	-2	4
U.S. ($ MM)		6,637	-8	%	-8	—	N/A
Foreign ($ MM)		5,237	12	%	5	-5	11